Dimenhydrinate

MECHANISM OF ACTION

Dimenhydrinate exerts its antiemetic effect primarily by blocking Histamine H1 receptor and inhibiting Muscarinic acetylcholine receptors in the brain. This action reduces stimulation of the Vestibular system and suppresses transmission of motion-related signals to the Central nervous system vomiting center. Additionally, its central sedative properties further contribute to the prevention and relief of nausea and vomiting associated with motion sickness.

PHARMACOKINETICS

Absorption

Dimenhydrinate is well absorbed from the gastrointestinal tract after oral administration. The onset of action typically occurs within 15–30 minutes, with peak plasma concentrations reached in about 1–2 hours. Its good absorption contributes to its effectiveness in preventing and treating motion sickness when taken prior to travel.

Distribution

Dimenhydrinate has a relatively large volume of distribution, indicating extensive distribution into body tissues. It readily crosses the Blood–brain barrier and is widely distributed in the Central nervous system, which accounts for its therapeutic antiemetic effects as well as its sedative properties.

Metabolism

Dimenhydrinate is primarily metabolized in the liver, where it is rapidly dissociated into its components, including diphenhydramine. The metabolic process occurs mainly via hepatic microsomal enzymes of the Cytochrome P450 enzyme system, producing inactive metabolites that are further processed for elimination.

Elimination

Dimenhydrinate is eliminated primarily through the kidneys after hepatic metabolism. Its metabolites, along with a small amount of unchanged drug, are excreted in the urine. The elimination half-life is generally around 3–6 hours, though this may vary depending on age, liver function, and individual metabolic differences.

PHARMACODYNAMICS

Dimenhydrinate acts primarily as an antagonist at Histamine H1 receptor and Muscarinic acetylcholine receptors, producing antiemetic, antivertigo, and antinauseant effects. By reducing stimulation of the Vestibular system and suppressing signals to the vomiting center in the Central nervous system, it effectively prevents motion-induced nausea.

ADMINISTRATION

Dimenhydrinate can be administered orally, rectally, or intravenously, depending on the formulation and clinical situation. Oral tablets, chewables, and liquid preparations are the most common for preventing or treating motion sickness, typically taken 30–60 minutes before travel. Rectal suppositories may be used when oral administration is not feasible, and intravenous administration is reserved for severe nausea or vomiting under medical supervision.

DOSAGE AND STRENGTH

Dimenhydrinate is available in oral tablets and chewables (50 mg), liquid suspension (15 mg/mL), and rectal suppositories (100 mg). For adults and children over 12 years, the typical dose is 50–100 mg every 4–6 hours as needed, not exceeding 400 mg per day. Children 6–12 years may receive 25–50 mg every 6–8 hours (maximum 150 mg/day), while children 2–6 years usually take 12.5–25 mg every 6–8 hours (maximum 75 mg/day). It is generally recommended to administer the drug 30–60 minutes before exposure to motion for optimal prevention of nausea and vomiting.

DRUG INTERACTIONS

Dimenhydrinate can interact with several other medications due to its sedative, anticholinergic, and CNS-depressant effects. Concomitant use with Alcohol, Benzodiazepines, Opioids, or Barbiturates can enhance drowsiness and sedation. Co-administration with other anticholinergic drugs (e.g., Atropine) may increase anticholinergic side effects such as dry mouth, urinary retention, and blurred vision.

FOOD INTERACTIONS

Dimenhydrinate can be taken with or without food, but certain dietary factors may influence its effects. Consuming alcohol or caffeine-containing beverages may alter the sedative or stimulatory effects of the drug, respectively—alcohol can enhance drowsiness, while caffeine may reduce its effectiveness against motion sickness.

CONTRAINDICATIONS

Dimenhydrinate is contraindicated in individuals with hypersensitivity to dimenhydrinate, diphenhydramine, or any component of the formulation. It should not be used in patients with severe asthma, respiratory depression, narrow-angle glaucoma, severe cardiovascular disease, or arrhythmias, as its anticholinergic and sedative effects may worsen these conditions. 

SIDE EFFECTS

• Drowsiness and sedation 

• Dizziness or lightheadedness 

• Dry mouth, nose, and throat 

• Blurred vision 

• Constipation or urinary retention 

• Headache

• Nervousness or irritability 

• Confusion or memory impairment.

OVER DOSAGE

Overdosage of Dimenhydrinate can lead to pronounced central nervous system and anticholinergic effects. Symptoms may include severe drowsiness, confusion, agitation, hallucinations, seizures, and in severe cases, coma. Anticholinergic manifestations such as dry mouth, dilated pupils, blurred vision, flushing, fever, tachycardia, and urinary retention may also occur. In children, paradoxical excitation (restlessness, irritability, insomnia) is more common.

TOXICITY

Dimenhydrinate toxicity is primarily related to its central nervous system (CNS) depressant and anticholinergic effects. Signs of toxicity include extreme drowsiness, confusion, agitation, hallucinations, seizures, and potentially coma in severe cases. Anticholinergic toxicity may present as dry mouth, dilated pupils, blurred vision, flushed skin, fever, tachycardia, and urinary retention. In children, paradoxical reactions such as hyperactivity, irritability, or insomnia are more common.